Incyte to Report Third Quarter Financial Results
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
The schedule for the press release and conference call/webcast is as follows:
• Q3 2024 Press Release: |
October 29, 2024 at 7:00 a.m. ET |
• Q3 2024 Conference Call: |
October 29, 2024 at 8:00 a.m. ET |
• Domestic Dial-In Number: |
877-407-3042 |
• International Dial-In Number: |
201-389-0864 |
• Conference ID Number: |
13749146 |
If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the
The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.
About Incyte
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in
For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241008194305/en/
Media
media@incyte.com
Investors
ir@incyte.com
Source: Incyte